April 3, 2025 – Munich, Germany – Conscio Group, a leading scientific service provider for the pharmaceutical industry, announces the appointment of Gary Chambers as Executive Vice President (EVP) of Strategy and Marketing. This strategic hire reflects Conscio Group’s ambitious plans in pharmaceutical sciences, especially in biologics and biosimilars, leveraging Mr. Chambers’ extensive expertise in these fields.
Prior to joining Conscio Group, Gary served as Vice President of Health Sciences at SGS Group for over a decade. He spearheaded sustainable growth strategies, including mergers and acquisitions, while driving innovation in emerging healthcare trends such as biosimilar testing and biologics quality control.
Commenting on his appointment, Gary Chambers stated: “I am honored to join Conscio Group at this pivotal time in its growth journey. The company’s commitment to advancing science in small molecules, biologics and biosimilars aligns perfectly with my passion for driving innovation that improves patient access to affordable therapies. I look forward to contributing to Conscio’s ambitious vision.”
Conscio Group CEO Stephan Holl added: “ I am thrilled to welcome Gary to Conscio and to our leadership team. He brings a rare mix of deep industry knowledge and a real passion for what we do – helping science move forward in ways that truly matter. His strategic mindset and focus on what our customers need most will play a big role as we grow and push into new territories.”
About Conscio Group
Conscio Group deep R&D, analytical and clinical testing expertise is essential to its customer centric approach in the development and clinical testing of Biologics, Biosimilars and complex small molecule drugs (e.g. highly potent APIs). With its interdisciplinary teams and focus on customer centricity, the scope spans from formulation development, analytical R&D, GMP manufacturing of IMPs (small molecules), bioanalytical testing, to clinical trials and quality control.
